Stock AnalizAmdocs Ltd. DOX
EDP Services · data as of November 13, 2026
Amdocs Ltd. (DOX) is a technology company listed in the US with a market value of about $4.8B. In the twelve months to September 30, 2026 it had revenue of $4.7B and net income of $497M, a net margin of 10.6%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (4/5); the weakest is future growth (1/5).
Key numbers: a P/E of 9.6, a price to free cash flow of 8.6, 5-year revenue growth of 4% a year, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 15% below the current price.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Profit margin improving
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B | $4.5B | $5.0B | $4.9B | $4.6B | $4.3B | $4.2B | $4.1B | $4.0B | $3.9B | $3.7B |
| Net income | $497M | $554M | $493M | $541M | $550M | $688M | $498M | $479M | $354M | $437M | $409M |
| Free cash flow | $562M | $645M | $619M | $698M | $530M | $715M | $453M | $528M | $326M | $503M | $490M |
| EPS (diluted) | $4.68 | $4.96 | $4.57 | $5.01 | $5.09 | $6.38 | $4.61 | $4.44 | $3.28 | $4.05 | $3.79 |
| Net margin | 10.6% | 12.2% | 9.8% | 11.1% | 12.0% | 16.1% | 11.9% | 11.7% | 8.9% | 11.3% | 11.0% |
| ROIC | — | — | 12.4% | 12.9% | 13.0% | 11.3% | 10.9% | 13.7% | 10.4% | 12.3% | 11.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $57.33, 28% above the current price; targets range from $46.00 to $63.00; the consensus rating is “Buy”; expected EPS is $5.38 for the fiscal year ending September 30, 2027.
Frequently asked questions
What is Amdocs’s P/E ratio?
About 9.6, based on the last twelve months of diluted earnings per share (forward P/E about 7.9).
Is Amdocs stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 15% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Amdocs pay a dividend?
Yes. The dividend yield is about 5.27%, and it has paid dividends for 10 years in our data.
Is Amdocs a good stock to buy?
We do not give buy or sell advice. Amdocs scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.